Effect of Mutation Order on Myeloproliferative Neoplasms

2015565 citationsJournal Articlebronze Open Access

Authors

Christina A. Ortmann · Medical Research Council

David G. Kent · Wellcome Trust

Jyoti Nangalia · University of Cambridge

Yvonne Silber · Stem Cell Institute

David C. Wedge · Wellcome Sanger Institute

Jacob Grinfeld · Medical Research Council

E. Joanna Baxter ·

Abstract

The order in which JAK2 and TET2 mutations were acquired influenced clinical features, the response to targeted therapy, the biology of stem and progenitor cells, and clonal evolution in patients with myeloproliferative neoplasms. (Funded by Leukemia and Lymphoma Research and others.).

Topics & Keywords

Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 7, pp. 601-612

DOI: 10.1056/nejmoa1412098

Field-Weighted Citation Impact: 46.34